Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.